Novartis Ag (NVS) 80.36 $NVS Alcon launches the

New Post Public Reply Private Reply Replies (0) Message Board

Sep 8, 2016 at 3:19 AM

Novartis Ag (NVS) 80.36 $NVS

Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience
Globe Newswire - 2 hrs 3 mins ago
Novartis International AG / Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)

Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur - Research and Markets
BusinessWire - Wed Sep 07, 3:35AM CDT
Research and Markets has announced the addition of the "Influenza Market (H1N1 Vaccines and Others) by Product (Influenza Vaccines and Influenza Drugs): Global Industry Perspective, Comprehensive Analysis and Forecast 2014 - 2020" report to their offering.
NVS: 80.36 (+0.21)

Foundation Fighting Blindness Sponsors Presentation by Retina Specialist James M. Maisel, M.D. on Macular Degeneration and Hereditary Retinal Degeneration
PRWeb - Wed Sep 07, 3:03AM CDT
James Maisel, MD will present "Macular Degeneration and Hereditary Retinal Degeneration" for the Foundation Fighting Blindness, Long Island Chapter Speaking Series, on September, 2016, 1:30-3:00 pm at the Farmingdale Public Library. The presentation is free to the public.
AGN: 238.42 (-0.70), NVS: 80.36 (+0.21)

Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:38AM CDT
Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler.
ANIP: 60.71 (-0.84), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), NVS: 80.36 (+0.21)

Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.84 (+0.07), NVS: 80.36 (+0.21)

Brazilian Pharmaceutical Market Outlook 2016-2026
PR Newswire Europe - Tue Sep 06, 8:03AM CDT
LONDON, September 6, 2016 /PRNewswire/ --
NVS: 80.36 (+0.21)

ROX Medical Raises $40M Financing
PR Newswire Europe - Tue Sep 06, 12:01AM CDT
ROX Medical, a privately held clinical-stage medical device company developing technologies for hypertension, announced today that it has secured $40M in Series E financing. Novartis Venture Fund and Apple Tree Partners led the round, joined by previous investors Versant Ventures and Domain Associates.
NVS: 80.36 (+0.21)

Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets
BusinessWire - Mon Sep 05, 10:12AM CDT
Research and Markets has announced the addition of the "Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
NVS: 80.36 (+0.21)

Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups
Globe Newswire - Sat Sep 03, 12:15AM CDT
Novartis International AG / Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), ARRY: 3.60 (unch), NVS: 80.36 (+0.21)

Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.87 (-0.37), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), BMY: 56.57 (-0.39), NVS: 80.36 (+0.21)

Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)

Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)

AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment
Globe Newswire - Wed Aug 31, 12:15AM CDT
Novartis International AG / AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Globe Newswire - Tue Aug 30, 3:01PM CDT
Novartis International AG / FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 238.42 (-0.70), GNRX: 24.86 (+0.46), PRGO: 90.39 (-1.68), AXGN: 9.00 (+0.06), AKRX: 26.69 (+0.23), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), AMPH: 19.03 (+0.12), NVS: 80.36 (+0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...